A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors-Reference-Cited by-同舟云学术

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Published:2020-01-22 Issue:10 Volume:26 Page:2290-2296
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Patel Sandip P.,Othus Megan,Chae Young Kwang,Giles Francis J.^ORCID,Hansel Donna E.,Singh Preet Paul^ORCID,Fontaine Annette,Shah Manisha H.,Kasi Anup^ORCID,Baghdadi Tareq Al,Matrana Marc,Gatalica Zoran,Korn W. Michael^ORCID,Hayward Jourdain,McLeod Christine,Chen Helen X.,Sharon Elad^ORCID,Mayerson Edward,Ryan Christopher W.,Plets Melissa,Blanke Charles D.,Kurzrock Razelle^ORCID

Funder

HHS | NIH | National Cancer Institute

Bristol-Myers Squibb

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. A Complete Response to Combined Immunotherapy in a Patient with an ATM plus SF3B1 Mutation and a Moderate Tumor Mutational Burden with a High-Grade Treatment-Emergent Neuroendocrine Prostate Cancer: Case Report and Review of the Literature;Case Reports in Oncology;2024-08-29

3. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913);Nature Communications;2024-08-08

4. Management of typical and atypical metastatic lung carcinoids: present and future perspectives;Clinical and Translational Oncology;2024-08-07

5. Multimodal Treatment With Nivolumab Contributes to Long-Term Survival in a Case of Unresectable Esophagogastric Junction Neuroendocrine Carcinoma;Cureus;2024-08-01